WO2006110728A3 - Immunogenic cmv tegument aggregates - Google Patents

Immunogenic cmv tegument aggregates

Info

Publication number
WO2006110728A3
WO2006110728A3 PCT/US2006/013451 US2006013451W WO2006110728A3 WO 2006110728 A3 WO2006110728 A3 WO 2006110728A3 US 2006013451 W US2006013451 W US 2006013451W WO 2006110728 A3 WO2006110728 A3 WO 2006110728A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
cmv
tegument
aggregates
invention
protein
Prior art date
Application number
PCT/US2006/013451
Other languages
French (fr)
Other versions
WO2006110728A2 (en )
Inventor
Earl R Kern
Mark Neal Prichard
William J Britt
Original Assignee
Uab Research Foundation
Earl R Kern
Mark Neal Prichard
William J Britt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention provides for cytomegalovirus protein tegument aggregates, pharmaceutical compositions, and the use thereof. The present invention provides for methods for anti-viral drug screening, production of CMV antigenic proteins, recombinant protein expression, immunogenic compounds such as CMV tegument aggregates with or without additional haptens, and vaccines useful for raising an immune response in an animal.
PCT/US2006/013451 2005-04-12 2006-04-11 Immunogenic cmv tegument aggregates WO2006110728A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US67026205 true 2005-04-12 2005-04-12
US60/670,262 2005-04-12

Publications (2)

Publication Number Publication Date
WO2006110728A2 true WO2006110728A2 (en) 2006-10-19
WO2006110728A3 true true WO2006110728A3 (en) 2007-12-06

Family

ID=37087624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013451 WO2006110728A3 (en) 2005-04-12 2006-04-11 Immunogenic cmv tegument aggregates

Country Status (1)

Country Link
WO (1) WO2006110728A3 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068850A1 (en) 2008-12-12 2010-06-17 Georgetown University Methods of diagnosing and treating cancer
WO2010127180A3 (en) 2009-04-30 2011-03-10 University Of Rochester Dc-stamp antibodies
EP2496697B1 (en) 2009-11-06 2017-04-12 Howard Hughes Medical Institute Genetically encoded calcium indicators and methods of use
US9719992B2 (en) 2011-10-07 2017-08-01 Howard Hughes Medical Institute Genetically encoded biosensors
EP3310380A1 (en) * 2015-06-18 2018-04-25 Vaximm AG Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156251A1 (en) * 1996-12-13 2002-10-24 Eric Prieur Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
US20030165522A1 (en) * 2000-03-23 2003-09-04 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156251A1 (en) * 1996-12-13 2002-10-24 Eric Prieur Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine
US20030165522A1 (en) * 2000-03-23 2003-09-04 Zaia John A. Protein kinase deficient, immunologically active CMVpp65 mutants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADAIR ET AL.: "The products of human cytomegalovirus genes UL23, UL24, Ul43 and US22 are tegument components", JOURNAL OF GENERAL VIROLOGY, vol. 83, 2002, pages 1315 - 1324, XP008091914 *
PRICHARD ET AL.: "Human Cytomegalovirus UL97 Kinase Is Required for the Normal Intranuclear Distribution of pp65 and Virion Morphogenesis", JOURNAL OF VIROLOGY, vol. 79, no. 24, 2005, pages 15494 - 15502, XP008092465 *
SEVERI ET AL.: "Human cytomegalovirus nuclear and cytoplasmic dense bodies", J. ARCH. VIROL., vol. 123, no. 1-2, March 1992 (1992-03-01), pages 193 - 207, XP008091384 *

Also Published As

Publication number Publication date Type
WO2006110728A2 (en) 2006-10-19 application

Similar Documents

Publication Publication Date Title
WO2004030608A3 (en) Nanoemulsion vaccines
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
WO2003045128A3 (en) SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2007103322A3 (en) Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2008068631A8 (en) Vaccines including antigen from four strains of influenza virus
WO2009001673A1 (en) Atp-containing immunoadjuvant
WO2007059116A3 (en) Geldanamycin derivatives and pharmaceutical compositions thereof
WO2006119510A3 (en) Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
Diaz-Dinamarca et al. Immunization with a Mixture of Nucleoprotein from Human Metapneumovirus and AbISCO-100 Adjuvant Reduces Viral Infection in Mice Model
m Gadzama et al. COMPOUNDING KILN FURNITURE USING CERAMICS COMPOSITE MATERIALS
WO2006042661A3 (en) Oligopeptides and their use in cosmetics
WO2004011611A3 (en) Taci antibodies and uses thereof
Wu et al. C26 TREATMENT OF RESPIRATORY INFECTIONS: Sulforaphane Increases Scavenger Receptor Marco Expression And Host Survival In A Model Of Post-Influenza Bacterial Pneumonia
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2006020208A3 (en) Therapeutic composition whit a botulinum neurotoxin
Wiwanitkit Cutaneous hypersensitivity in dengue infection and explanation of its pathogenesis by allergenicity assessment
WO2006038923A3 (en) Aryl substituted imidazonaphthyridines
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
WO2006031560A3 (en) Process for concentration of antibodies and therapeutic products thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749735

Country of ref document: EP

Kind code of ref document: A2